07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Cleveland BioLabs, Bioprocess Capital Ventures deal

Cleveland sold 75% of its equity stake in Incuron for about $3 million to Dr. Mikhail Mogutov, who is the chairman of Incuron. Mogutov has an option to purchase Cleveland’s remaining stake for $1 million....
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

Curaxin quinacrine: Phase I data

A dose-escalation Phase I trial in 32 patients with advanced breast, gastric, hepatic, pancreatic and colorectal cancer showed that once-daily oral CBL0102 was generally well tolerated with skin discoloration, gastrointestinal disorders and hepatic transaminase elevations...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

intravenous CBL0137: Phase I started

Cleveland BioLabs said Incuron LLC JV (Moscow, Russia) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 10, 20, 30, 40, 50 and 62.5 mg/m 2 IV CBL0137 given on days 1, 8 and...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

Cleveland BioLabs preclinical data

In a mouse model of breast cancer, chronic administration of oral CBL0137 inhibited mammary tumor onset, delayed tumor progression and prolonged survival in a dose-dependent manner. Additionally, CBL0137 did not cause any detectable changes in...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

Cleveland BioLabs preclinical data

In a mouse model of neuroblastoma, both oral and IV CBL0137 plus standard chemotherapy - cyclophosphamide and topotecan - led to complete tumor regression in 100% of mice vs. 0% for CBL0137 alone and 0%...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Cleveland BioLabs cancer news

Cleveland BioLabs said Bioprocess Capital Ventures LLC , a Russian venture company, invested about $6 million into the companies' Incuron LLC JV (Moscow, Russia). Incuron was formed in 2009 to develop the biotech's portfolio of...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Cleveland BioLabs cancer news

Incuron LLC, a JV formed by Cleveland BioLabs and the Russian venture company Bioprocess Capital Ventures LLC, received a $5 million grant from the Russian government's Skolkovo initiative to develop Curaxins to treat cancer. Incuron...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

Curaxin quinacrine: Phase Ib started

Incuron LLC began an open-label, Russian Phase Ib trial of Curaxin quinacrine in up to 36 patients with liver metastases of solid tumors of epithelial origin or primary advanced hepatic carcinoma for which standard therapy...
07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Cleveland BioLabs, Incuron LLC deal

Incuron, a JV formed by Cleveland BioLabs and Russian venture company Bioprocess Capital Ventures LLC in 2009 to develop the biotech's portfolio of Curaxin compounds for cancer, received a $5.7 million investment from Bioprocess. The...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Company News

Cleveland BioLabs deal

Cleveland BioLabs and Russian venture company Bioprocess Capital Ventures will form a JV to develop the biotech's portfolio of Curaxin compounds for cancer. Cleveland BioLabs will own 51% of the JV, and Bioprocess will own...